DMS Imaging (XBRU:ALIMG) Debt-to-Equity : 1.81 (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is DMS Imaging Debt-to-Equity?

DMS Imaging's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €6.06 Mil. DMS Imaging's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €11.86 Mil. DMS Imaging's Total Stockholders Equity for the quarter that ended in Dec. 2023 was €9.89 Mil. DMS Imaging's debt to equity for the quarter that ended in Dec. 2023 was 1.81.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for DMS Imaging's Debt-to-Equity or its related term are showing as below:

XBRU:ALIMG' s Debt-to-Equity Range Over the Past 10 Years
Min: -4.93 Med: 0.03 Max: 1.81
Current: 1.81

During the past 12 years, the highest Debt-to-Equity Ratio of DMS Imaging was 1.81. The lowest was -4.93. And the median was 0.03.

XBRU:ALIMG's Debt-to-Equity is ranked worse than
94.39% of 1069 companies
in the Biotechnology industry
Industry Median: 0.14 vs XBRU:ALIMG: 1.81

DMS Imaging Debt-to-Equity Historical Data

The historical data trend for DMS Imaging's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DMS Imaging Debt-to-Equity Chart

DMS Imaging Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

-1.17

-0.94

1.16

1.38

1.81

DMS Imaging Semi-Annual Data
	Dec13	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															1.16	1.18	1.38	1.58	1.81

Competitive Comparison of DMS Imaging's Debt-to-Equity

For the Biotechnology subindustry, DMS Imaging's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

DMS Imaging's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DMS Imaging's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where DMS Imaging's Debt-to-Equity falls into.

DMS Imaging Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

DMS Imaging's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(6.058	+	11.863)	/	9.892
	=	1.81

DMS Imaging's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(6.058	+	11.863)	/	9.892
	=	1.81

DMS Imaging (XBRU:ALIMG) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

DMS Imaging Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of DMS Imaging's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

DMS Imaging (XBRU:ALIMG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DMS Imaging SA (XBRU:ALIMG) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

AS0:Germany

Address

7 Rue des Chasseurs Ardennais, Liege, BEL, 4031

Website

https://www.dms-imaging.com

DMS Imaging SA is a clinical-stage biopharmaceutical company. The company is engaged in the development and future commercialization of a range of breakthrough immunotherapy products for the treatment of allergies, based on its ASIT+ technology platform. Its lead product is gp-ASIT+, a phase III trial for the treatment of grass pollen rhinitis. Its pipeline products consist of hdm-ASIT+ for the treatment of house dust mite asthma; and pnt-ASIT+ for the treatment of peanut allergy.

DMS Imaging (XBRU:ALIMG) Headlines

No Headlines